Beating the odds: Efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer

British Journal of Clinical Pharmacology

Volumn 81, Issue 1, 2016, Pages 124-130

  Launay, Manon ^a   Dahan, Laetitia ^a   Duval, Manon ^a   Rodallec, Anne ^a   Milano, Gérard ^b   Duluc, Muriel ^a   Lacarelle, Bruno ^a,c   Ciccolini, Joseph ^a,c   Seitz, Jean Francois ^a  

^a TIMONE HOSPITAL   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

5 FU; Adaptive dosing; Digestive oncology; DPD deficency; Efficacy; Toxicity

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VOMITING; DIGESTIVE SYSTEM NEOPLASMS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; FEMALE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DIGESTIVE SYSTEM NEOPLASMS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED;

EID: 84953363780     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12790     Document Type: Article

References (30)

1. Aklilu M, Eng C. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol 2011; 8: 649-59.
2. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 2010; 9: 224-8.
3. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N. Severe toxicity related to the 5-fluorouracil/leucovorin combination (the mayo clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol 2003; 26: 103-6.
4. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, Schneider M, Demard F, Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-53.
5. Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 2006; 6: 288-96.
6. van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J 2013; 13: 389-95.
7. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2099-105.
8. Ibrahim T, Di Paolo A, Amatori F, Mercatali L, Ravaioli E, Flamini E, Sacanna E, Del Tacca M, Danesi R, Amadori D. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. J Clin Pharmacol 2012; 52: 361-9.
9. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracilbased chemotherapy. Ther Drug Monit 2006; 28: 678-85.
10. Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011; 67: 49-56.
11. Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939-50.
12. Mercier C, Ciccolini J. Univ severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 2007; 28: 597-8.
13. Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L, Loupakis F, Allegrini G, Falcone A, Del Tacca M, Danesi R. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. Br J Clin Pharmacol 2009; 67: 132-4.
14. Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5- fluorouracil toxicity. Pharmacogenomics 2011; 12: 1321-36.
15. Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord JP, Toulas C, Chatelut E. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin Pharmacol Ther 2015; Aug 11. doi:. doi:10.1002/cpt.210. [Epub ahead of print].
16. Del Re M, Michelucci A, Di Leo A, Cantore M, Bordonaro R, Simi P, Danesi R. Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. EPMA J 2015; 6: 17.
17. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14 + 1 G>A and 2846 A>T genotyping for the prediction of severe fluoropyrimidinerelated toxicity: a meta-analysis. Pharmacogenomics 2013; 14: 1255-72.
18. Li Q, Liu Y, Zhang HM, Huang YP, Wang TY, Li DS, Sun HZ. Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. Gastroenterol Res Pract 2014; 2014: 827989.
19. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32: 1031-9.
20. Lee SY, McLeod HL. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. J Pathol 2011; 223: 15-27.
21. Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E, Pietrantonio F. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. Int J Mol Sci 2015; 16: 8884-95.
22. Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 1998; 46: 1-4.
23. Sistonen J, Büchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiadèr CR. Predicting 5- fluorouracil toxicity: DPD genotype and 5, 6-dihydrouracil: uracil ratio. Pharmacogenomics 2014; 15: 1653-66.
24. van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg AB, Maring JG. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPDdeficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 2011; 68: 1611-7.
25. Carlsson G, Odin E, Gustavsson B, Wettergren Y. Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 2014; 74: 757-63.
26. Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Milano G, Seitz JF, Lacarelle B. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 2006; 58: 272-5.
27. Mercier C, Ciccolini J. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 2007; 28: 597-8.
28. Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, Lastella M, Federici F, Iannopollo M, Falcone A, Ricci S, Del Tacca M, Danesi R. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res 2008; 14: 2749-55.
29. Woloch C, Di Paolo A, Marouani H, Bocci G, Ciccolini J, Lacarelle B, Danesi R, Iliadis A. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. Curr Top Med Chem 2012; 12: 1713-9.
30. van Kuilenburg AB, Häusler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, Behnke D, Schwabe W, Jabschinsky K, Maring JG. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905 + 1 G >a mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012; 51: 163-74.